Primary GBM, accounting for over 90% of human GBMs, develops rapidly or de novo with no prior clinical disease. Large-scale genomic analyses have contributed greatly to the definition of the overall glioma landscape and datasets (TCGA) have enabled the division of GBMs into subclasses based on their genomic, transcriptomic, and signal transduction patterns. Sadly, despite these insights into the genetics of the disease and advances in neurosurgery, radiation and chemotherapy, its dismal prognosis has not changed significantly. The current paradigm for glioblastoma (GBM) therapy is based on the concept that each patient is treated with a protocol that is most likely to prolong life (temozolamide and radiation) in a majority of patients. The treatment may not be efficacious for any given individual even though it may work with most patients with a similar pathology. If the treatment fails, second-line treatments, usually experimental are administered, although by this time it may be too late for many patients with glioblastoma. This concept is obviously unacceptable in the current era wherein the technology for whole genome sequencing is a reality and thus enabling personalized medicine using targeted agents based on genetic alterations of each patient is possible. Project 1 will investigate in mouse model using human GBM explants, if stratification of patients based on the four molecular classes of GBM followed by optimization of single and combination therapies for each of these subclasses can enhance outcomes. Project 2 using a mouse model of adult onset GBM, investigate the sequential accumulation of genetic lesions that initiate gliomagenesis and also identify genetic/proteomic alterations that transform a slow growing lesion into aggressive disease, as well as alterations that result in therapeutic resistance. This information will be used to test the hypothesis that targeted inhibition of initiating oncogenic pathways early in gliomagenesis will enhance survival. Project 3 will undertake prospective and retrospective GBM clinical trials to evaluate quantitative MR biomarker metrics for early prediction of treatment efficacy and GBM recurrence. The overall integration of the program components will provide novel insights into the oncogenic evolution of the disease (Project 2) and the application of targeted agents directed against these oncogenic events in an individualized manner (Project 1) with the use of novel imaging technologies as predictive surrogates (Project 3) will significantly impact this patient population. All three research projects will be supported by four cores, the administrative core (Core A), an imaging core (Core B), a bioinformatics core (Core C) and the biostatistics core (Core D).

Public Health Relevance

Overall, this research effort will provide the rationale for initiation of clinical trias with combinations of molecularly targeted therapies for the treatment of brain tumors. In addition, imaging biomarkers for early assessment of treatment response and recurrence will be identified and validated. The overall project will provide the foundation for clinical delivery of individualized patient care leading to improved outcome.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA085878-11
Application #
8689941
Study Section
Special Emphasis Panel (ZCA1-RPRB-W (J1))
Program Officer
Menkens, Anne E
Project Start
2000-04-01
Project End
2018-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
11
Fiscal Year
2014
Total Cost
$1,955,178
Indirect Cost
$617,813
Name
University of Michigan Ann Arbor
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Galbán, C J; Hoff, B A; Chenevert, T L et al. (2016) Diffusion MRI in early cancer therapeutic response assessment. NMR Biomed :
Chen, Daiqin; Dougherty, Casey A; Yang, Dongzhi et al. (2016) Radioactive Nanomaterials for Multimodality Imaging. Tomography 2:3-16
Masch, William R; Wang, Page I; Chenevert, Thomas L et al. (2016) Comparison of Diffusion Tensor Imaging and Magnetic Resonance Perfusion Imaging in Differentiating Recurrent Brain Neoplasm From Radiation Necrosis. Acad Radiol 23:569-76
Van Dort, Marcian E; Hong, Hao; Wang, Hanxiao et al. (2016) Discovery of Bifunctional Oncogenic Target Inhibitors against Allosteric Mitogen-Activated Protein Kinase (MEK1) and Phosphatidylinositol 3-Kinase (PI3K). J Med Chem 59:2512-22
Ross, Brian D (2016) Demonstration of an Inline Publication Image Viewer: The Future of Radiological Publishing. Tomography 2:1-2
Aryal, Madhava P; Chenevert, Thomas L; Cao, Yue (2016) Impact of uncertainty in longitudinal T1 measurements on quantification of dynamic contrast-enhanced MRI. NMR Biomed 29:411-9
Nyati, Shyam; Chator, Areeb; Schinske, Katerina et al. (2016) A Requirement for ZAK Kinase Activity in Canonical TGF-β Signaling. Transl Oncol 9:473-481
Ceccarelli, Michele; Barthel, Floris P; Malta, Tathiane M et al. (2016) Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell 164:550-63
Tang, Ming; Verhaak, Roel Gw (2016) A Molecular Take on Malignant Rhabdoid Tumors. Trends Cancer 2:217-218
Lemasson, Benjamin; Wang, Hanxiao; Galbán, Stefanie et al. (2016) Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model. Neoplasia 18:82-9

Showing the most recent 10 out of 140 publications